Abstract
BECAUSE PRETERM birth is the leading cause of nenonatal morbidity and mortality, there is continued interest in identification of pharmacologic agents that inhibit premature labor, In the United States, the use of beta-adrenergic tocolytic agents has increased over the past few years, and probably will continue to increase because of the recent Food and Drug Administration approval of ritodrine. Thus, careful assessment of the shortand long-term effects of in utero exposure to tocolytic agents is essential. We recently conducted studies to assess the acute neonatal problems associated with isoxsuprine exposure l'z and to determine the maternal factors contributing to success and failure of tocolytic therapy. 3 This study examines the developmental outcome of very-low-birth-weight (VLBW) infants who received antenatal exposure to isoxsuprine and were carefully monitored in the newborn period for drugassociated symptoms, and compares it with the outcome of similar infants who were not exposed to isoxsuprine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
